“Dose-Dependent Infectivity of Aseptic, Purified, Cryopreserved Plasmodium falciparum 7G8 Sporozoites in Malaria-Naive Adults.”, J Infect Dis, vol. 220, no. 12, pp. 1962-1966, 2019.
, “PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: A randomized, placebo-controlled trial with controlled human malaria infection.”, PLoS Pathog, vol. 17, no. 5, p. e1009594, 2021.
, “PfSPZ-CVac Malaria Vaccine Demonstrates Safety Among Malaria-experienced Adults: A Randomized, Controlled Phase 1 Trial”, EClinicalMedicine, vol. 52, p. 101579, 2022.
, “Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine.”, Science, vol. 341, no. 6152, pp. 1359-65, 2013.
, “Safety and Differential Antibody and T-Cell Responses to the Sporozoite Malaria Vaccine, PfSPZ Vaccine, by Age in Tanzanian Adults, Adolescents, Children, and Infants.”, Am J Trop Med Hyg, vol. 100, no. 6, pp. 1433-1444, 2019.
, “Safety and Differential Antibody and T-Cell Responses to the Sporozoite Malaria Vaccine, PfSPZ Vaccine, by Age in Tanzanian Adults, Adolescents, Children, and Infants.”, Am J Trop Med Hyg, vol. 100, no. 6, pp. 1433-1444, 2019.
, “Safety and Differential Antibody and T-Cell Responses to the Sporozoite Malaria Vaccine, PfSPZ Vaccine, by Age in Tanzanian Adults, Adolescents, Children, and Infants.”, Am J Trop Med Hyg, vol. 100, no. 6, pp. 1433-1444, 2019.
, “Safety and Differential Antibody and T-Cell Responses to the Sporozoite Malaria Vaccine, PfSPZ Vaccine, by Age in Tanzanian Adults, Adolescents, Children, and Infants.”, Am J Trop Med Hyg, vol. 100, no. 6, pp. 1433-1444, 2019.
,